WCN26-6297 SHARED DECISION-MAKING IN HYPERPHOSPHATEMIA MANAGEMENT USING TENAPANOR HYDROCHLORIDE IN DIALYSIS PRACTICE: A PATIENT-CENTERED APPROACH EMBEDDED IN DAILY EDUCATIONAL CULTURE

Read full text Summarise with VIRAT
Authors: Toko Endo, Chiduru Hasegawa, Yoshiatsu Utsumi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Phosphate binder therapy for hyperphosphatemia in dialysis patients often leads to polypharmacy and poor adherence due to excessive pill burden. In routine dialysis practice, improving medication adherence and fostering patient engagement have become essential aspects of quality care. Tenapanor hydrochloride, a novel intestinal sodium/hydrogen exchanger 3 (NHE3) inhibitor approved in 2024 in Japan, offers a new mechanism that may simplify phosphate management and reduce the number of concomitant binders.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Dialysis and Renal Disease Management Patient-Provider Communication in Healthcare

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105293–105293
Publication date
25 March 2026
Language
EN